DRCR.net Protocol T study: 1- and 2-year results
News
Sanjay Sharma gives an overview of both the 1- and 2-year results from the DRCR.net Protocol T study comparing aflibercept, ranibizumab and bevacizumab.
Sanjay Sharma gives an overview of both the 1- and 2-year results from the DRCR.net Protocol T study comparing aflibercept, ranibizumab and bevacizumab.